Hematologic toxicity of sodium valproate Academic Article Article uri icon

Overview

MeSH Major

  • Asthma
  • Bronchoalveolar Lavage Fluid
  • Glycoproteins

abstract

  • Hematologic toxicities of valproate are common, vary in onset and severity, are recurrent, transient, or persistent, and usually occur with a serum valproate level greater than 100 microg/mL. In most situations, even when highly clinically significant, they can be reversed with dosage reduction; drug discontinuation is rarely required. Potential adverse effects such as thrombocytopenia and leukopenia are easily detected by laboratory monitoring, which should be continued indefinitely at least on a quarterly basis. Caution for elective surgery is advised; preoperative coagulation studies should be done, including platelet function studies and von Willebrand factor levels. Perioperative use of DDAVP to increase von Willebrand factor levels and improve platelet function is appropriate in some cases.

publication date

  • December 2000

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1097/00043426-200001000-00012

PubMed ID

  • 10695824

Additional Document Info

start page

  • 62

end page

  • 5

volume

  • 22

number

  • 1